Cormorant Asset Management, LP Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001583977

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidHealth TiltHigh Turnover how tags are computed

Q3 2024 · 45 positions · Total reported value $1.89B · Top-10 concentration 59.0% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 81.4% · 9 new · 37 cut · 2 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -24.1% · vs SPY -26.2% · Prev Value $1.95B — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -13.0% · vs SPY -15.1% · Latest Value $1.40B — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q3 2024 13F filing, Cormorant Asset Management, LP disclosed 45 equity positions with a combined reported value of $1.89B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 59.0% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2024 were MLTX ($428.28M), PCVX ($114.27M), ACLX ($104.39M). By sector, the heaviest allocations are Health Care 72.3%, Industrials 3.5%. Versus the prior quarter, allocation shifted toward Other (+2.3pp) and away from Industrials (-0.7pp), Health Care (-1.6pp).

Versus the prior quarter, Cormorant Asset Management, LP opened 9 new positions, trimmed 37 and fully exited 2, a turnover rate of 81.4% of positions. The portfolio's overlap with the prior quarter was 77% of names.

The largest new positions opened in Q3 2024 were BIOA ($33.89M), MBX ($18.19M), ANAB ($11.47M).

Of the 2 positions fully exited versus the prior quarter, the largest were SRPT ($19.75M), CGEM ($19.62M), IDYA ($8.60M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2024)

  • BIOA BIOAGE LABS INC · $33.89M
  • MBX MBX BIOSCIENCES INC · $18.19M
  • ANAB ANAPTYSBIO INC · $11.47M
  • ARTV ARTIVA BIOTHERAPEUTICS INC · $1.60M

Fully Exited (vs previous quarter)

  • SRPT SAREPTA THERAPEUTICS INC · prev qtr: $19.75M
  • CGEM CULLINAN THERAPEUTICS INC · prev qtr: $19.62M
  • IDYA IDEAYA BIOSCIENCES INC · prev qtr: $8.60M
  • IBRX IMMUNITYBIO INC · prev qtr: $7.90M
  • LNTH LANTHEUS HLDGS INC · prev qtr: $6.02M
  • MRSN MERSANA THERAPEUTICS INC · prev qtr: $5.23M
  • SIGA SIGA TECHNOLOGIES INC · prev qtr: $3.79M
  • CMPX COMPASS THERAPEUTICS INC · prev qtr: $2.03M

Insider Transactions (Form 4)

Latest Cormorant Asset Management, LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-10-29 Sell Corbus Pharmaceuticals Holdings, Inc. 425,000 $4.10 SEC filing
2026-08-10 Buy BlossomHill Therapeutics, Inc. 312,500 $16.00 SEC filing
2026-08-10 Conversion BlossomHill Therapeutics, Inc. 1,701,541 — SEC filing
2026-08-10 Conversion BlossomHill Therapeutics, Inc. 1,599,993 — SEC filing
2026-04-28 Sell BRIGHT MINDS BIOSCIENCES INC. 109,331 $89.50 SEC filing

All insider transactions →

Fund Profile

Cormorant Asset Management, LP, based in Boston, MA, United States, files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q3 2026) lists 57 positions worth $1.40B in total. HoldingsHub carries 13 quarters of its filings (Q3 2023–Q3 2026).

Firm Snapshot

  • Headquarters: BOSTON, MA, United States
  • SEC registration: 801-79513 (status: Approved), registered 2014-04-15
  • Regulatory AUM (Form ADV): $3.84B as of 2026-05-27
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 7 private funds, of which 1 hedge funds

Portfolio Structure

  • 57 positions · $1.40B reported value (Q3 2026)
  • Top 10 holdings = 56.4% of reported value
  • Largest position: PBLS (PARABILIS MEDICINES INC) at 10.7%
  • Average position size: $24.53M

Sector Tilt

  • Health Care 92.7%
  • Industrials 1.3%
  • Financials 1.1%
  • (classified holdings cover 95% of value)

Quarterly Activity

  • Q3 2026: 9 new, 1 added, 37 reduced, 2 exited
  • 10 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 72.3%
Other 24.2%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 8.49M $428.28M 22.71%
22.71%
Hold
2 1.00M $114.27M 6.06%
6.06%
Reduce
3 1.25M $104.39M 5.54%
5.54%
Reduce
4 2.79M $93.01M 4.93%
4.93%
Hold
5 3.41M $90.92M 4.82%
4.82%
Add
6 8.32M $66.52M 3.53%
3.53%
Hold
7 2.94M $60.23M 3.19%
3.19%
Hold
8 1.10M $56.21M 2.98%
2.98%
Reduce
9 870.00K $50.06M 2.65%
2.65%
Add
10 2.38M $49.00M 2.60%
Form 4 · 1 →
2.60%
Add
11 1.05M $48.23M 2.56%
2.56%
Add
12 1.05M $47.70M 2.53%
2.53%
Hold
13 1.86M $47.31M 2.51%
2.51%
Hold
14 2.47M $41.00M 2.17%
2.17%
Add
15 2.56M $40.96M 2.17%
2.17%
Add
16 740.00K $36.97M 1.96%
1.96%
Reduce
17 975.00K $36.79M 1.95%
1.95%
Hold
18 500.00K $36.50M 1.94%
1.94%
Reduce
19 3.57M $36.07M 1.91%
1.91%
Hold
20 400.00K $35.95M 1.91%
1.91%
Hold
21 1.63M $33.89M 1.80%
1.80%
New
22 2.91M $30.40M 1.61%
1.61%
Hold
23 1.47M $27.16M 1.44%
1.44%
Hold
24 2.13M $24.54M 1.30%
1.30%
Hold
25 2.15M $22.93M 1.22%
1.22%
Hold
26 1.18M $21.82M 1.16%
1.16%
Hold
27 2.33M $21.62M 1.15%
1.15%
Reduce
28 400.00K $20.96M 1.11%
1.11%
Reduce
29 401.96K $20.09M 1.06%
1.06%
Reduce
30 1.55M $19.68M 1.04%
1.04%
Reduce
31 1.45M $19.07M 1.01%
1.01%
Hold
32 700.00K $18.19M 0.96%
0.96%
New
33 500.00K $16.45M 0.87%
0.87%
Hold
34 585.46K $13.76M 0.73%
0.73%
Add
35 342.46K $11.47M 0.61%
0.61%
New
36 265.83K $8.88M 0.47%
0.47%
Hold
37 400.00K $7.27M 0.39%
0.39%
Reduce
38 1.00M $6.60M 0.35%
0.35%
Hold
39 427.16K $5.25M 0.28%
0.28%
Hold
40 107.34K $4.50M 0.24%
0.24%
Hold
41 593.04K $3.97M 0.21%
0.21%
Hold
42 1.39M $2.62M 0.14%
0.14%
Hold
43 350.00K $1.69M 0.09%
0.09%
Hold
44 103.63K $1.60M 0.09%
0.09%
New
45 496.75K $998.47K 0.05%
0.05%
Hold

FAQ

What did Cormorant Asset Management, LP buy in 2024-Q3?

In its 2024-Q3 13F filing, Cormorant Asset Management, LP reported 45 equity positions worth $1.89B in aggregate; its largest disclosed positions were MLTX ($428.28M), PCVX ($114.27M), ACLX ($104.39M).

How large is Cormorant Asset Management, LP's portfolio?

Cormorant Asset Management, LP reported $1.89B of long equity holdings across 45 positions as of 2024-Q3. Top-10 holdings account for 59.0% of reported value.

What is Cormorant Asset Management, LP's investment style?

HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/cormorant-asset-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →